Alto Neuroscience, Inc. (NYSE:ANRO) Stock Has Consensus Target Price of $37.25 According to Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $37.88.

Several brokerages have commented on ANRO. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. HC Wainwright upped their price target on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, October 19th. BTIG Research increased their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wedbush raised their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 24,056 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the transaction, the chief financial officer directly owned 24,060 shares in the company, valued at $621,229.20. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.25% of the company’s stock.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Sterling Capital Management LLC raised its holdings in shares of Alto Neuroscience by 1,045.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after buying an additional 962 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Alto Neuroscience by 48,581.8% during the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after buying an additional 5,344 shares during the period. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience during the second quarter valued at about $226,000. Revisor Wealth Management LLC bought a new position in shares of Alto Neuroscience during the first quarter valued at about $385,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Alto Neuroscience in the first quarter worth about $534,000.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $21.96 on Friday. The company has a market capitalization of $861.87 million, a P/E ratio of -9.08 and a beta of 1.31. The business has a fifty day simple moving average of $29.45 and a two-hundred day simple moving average of $26.31. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. Alto Neuroscience has a 1 year low of $10.20 and a 1 year high of $37.48.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. On average, analysts expect that Alto Neuroscience will post -2.69 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.